Factors associated with duloxetine treatment among patients with major depressive disorder in Veterans Health Administration: a retrospective study

References

• Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003;289:3095-105
   PubMed Web of Science ®Google Scholar
• Birnbaum H, Greenberg PE, Tang J, et al. Antidepressant treatment patterns and costs among US employees. J Med Econ 2009;12:36-45
   PubMedGoogle Scholar
• Murray CJL, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997;349:1436-42
   PubMed Web of Science ®Google Scholar
• Brannan SK, Mallinckrodt CH, Brown EB, et al. Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. [See comment.] J Psychiatr Res 2005;39:43-53
   PubMed Web of Science ®Google Scholar
• Stewart DE. Physical symptoms of depression: unmet needs in special populations. J Clin Psychiatry 2003;64(Suppl. 7):12-16
   PubMedGoogle Scholar
• McIntyre RS, Konarski JZ. Duloxetine: pharmacoeconomic implications of an antidepressant that alleviates painful physical symptoms. Expert Opin Pharmacother 2005;6:707-13
   PubMed Web of Science ®Google Scholar
• Fishbain DA. The association of chronic pain and suicide. Semin Clin Neuropsychiatry 1999;4:221-7
   PubMedGoogle Scholar
• Fava M, Wiltse C, Walker D, et al. Predictors of relapse in a study of duloxetine treatment in patients with major depressive disorder. J Affect Disord 2009;113:263-71
   PubMed Web of Science ®Google Scholar
• Arnold LM, Meyers AL, Sunderajan P, et al. The effect of pain on outcomes in a trial of duloxetine treatment of major depressive disorder. Ann Clin Psychiatry 2008;20:187-93
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Practice Guideline for the Treatment of Patients With Major Depressive Disorder, 2nd Edn. 2005
   Google Scholar
• Department of Veterans Affairs, Department of Defense. VA/DoD Clinical Practice Guideline for Management of Major Depressive Disorder (MDD). 2009
   Google Scholar
• Bair MJ, Robinson RL, Eckert GJ, et al. Impact of pain on depression treatment response in primary care. Psychosom Med 2004;66:17-22
   PubMed Web of Science ®Google Scholar
• Brecht S, Courtecuisse C, Debieuvre C, et al. Efficacy and safety of duloxetine 60 mg once daily in the treatment of pain in patients with major depressive disorder and at least moderate pain of unknown etiology: a randomized controlled trial. [See comment.] J Clin Psychiatry 2007;68:1707-16
   PubMed Web of Science ®Google Scholar
• Schatzberg AF. Efficacy and tolerability of duloxetine, a novel dual reuptake inhibitor, in the treatment of major depressive disorder. J Clin Psychiatry 2003;64(Suppl. 13):30-7
   PubMed Web of Science ®Google Scholar
• Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol 2004;24:389-99
   PubMed Web of Science ®Google Scholar
• Vis P, van Baardewijk M, Einarson T. Duloxetine and venlafaxine-XR in the treatment of major depressive disorder: a meta-analysis of randomized clinical trials. Ann Pharmacother 2005;39:1798-807
   PubMed Web of Science ®Google Scholar
• Goldstein DJ, Lu Y, Detke MJ, et al. Effects of duloxetine on painful physical symptoms associated with depression. Psychosomatics 2004;45:17-28
   PubMed Web of Science ®Google Scholar
• Raskin J, Wiltse CG, Siegal A, et al. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am J Psychiatry 2007;164:900-9
   PubMed Web of Science ®Google Scholar
• Howland RH, Wilson MG, Kornstein SG, et al. Factors predicting reduced antidepressant response: experience with the SNRI duloxetine in patients with major depression. Ann Clin Psychiatry 2008;20:209-18
   PubMed Web of Science ®Google Scholar
• Perahia DGS, Quail D, Desaiah D, et al. Switching to duloxetine in selective serotonin reuptake inhibitor non- and partial-responders: effects on painful physical symptoms of depression. J Psychiatr Res 2009;43:512-18
   PubMed Web of Science ®Google Scholar
• Rubin RR, Ma Y, Peyrot M, et al. Antidepressant medicine use and risk of developing diabetes during the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study. Diabetes Care 2010 [Epub ahead of print]
   Google Scholar
• Shi L, Thiebaud P, McCombs JS. The impact of unrecognized bipolar disorders for patients treated for depression with antidepressants in the fee-for-services California Medicaid (Medi-Cal) program. J Affect Disord 2004;82:373-83
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services. ICD-9-CM Official Guidelines for Coding and Reporting. 2008 [cited 2010 Oct 19]; Available from: http://www.flashcode.com/help_resources/icdguide.pdf
   Google Scholar
• O'Connor PJ, Rush WA, Pronk NP, et al. Identifying diabetes mellitus or heart disease among health maintenance organization members: sensitivity, specificity, predictive value, and cost of survey and database methods. Am J Manag Care 1998;4:335-42
   PubMed Web of Science ®Google Scholar
• Palos GR, Mendoza TR, Mobley GM, et al. Asking the community about cutpoints used to describe mild, moderate, and severe pain. J Pain 2006;7:49-56
   PubMed Web of Science ®Google Scholar
• Sullivan MD, Edlund MJ, Fan MY, et al. Trends in use of opioids for non-cancer pain conditions 2000–2005 in commercial and Medicaid insurance plans: the TROUP study. Pain 2008;138:440-9
   PubMed Web of Science ®Google Scholar
• Maloney P, McIntosh EG. Chronic low back pain and depression in a sample of veterans. Percept Mot Skills 2001;92:348
   PubMed Web of Science ®Google Scholar
• Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 2001;25:871-80
   PubMed Web of Science ®Google Scholar
• Passik SD. Issues in long-term opioid therapy: unmet needs, risks, and solutions. Mayo Clin Proc 2009;84:593-601
   PubMed Web of Science ®Google Scholar